Elevated levels of plasminogen activator inhibitor-1 may account for the altered fibrinolysis by keloid fibroblasts

Journal of Investigative Dermatology

Volumn 106, Issue 5, 1996, Pages 1007-1011

  Tuan, Tai Lan ^a,b   Zhu, Judy Y ^a   Sun, Bo ^a   Nichter, Larry S ^a   Nimni, Marcel E ^a   Laug, Walter E ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

fibrin gel; Transforming growth factor 1 (TGF 1); Urokinase type plasminogen activator (uPA)

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA1; UROKINASE;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; HYPERTROPHIC SCAR; KELOID; PRIORITY JOURNAL; WOUND HEALING;

EID: 0029916476     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/1523-1747.ep12338552     Document Type: Article

References (44)

1. Abergel RP, Uitto J: Fibrotic skin diseases. Keloids as a model to study the mechanisms of collagen deposition in tissues. In: Uitto J, Perejda AJ (eds.). Connective Tissue Diseases. Marcel Dekker, Inc., New York, 345-366, 1987
2. Alexander CM, Werb Z: Proteinases and extracellular matrix remodeling. Curr Opin Cell Biol 1:974-982, 1989
3. Babu M, Diegelmann R, Oliver N: Fibronectin is overproduced by keloid fibroblasts during abnormal wound healing. Mol Cell Biol 9:1642-1650, 1989
4. Babu M, Diegelmann R, Oliver N: Keloid fibroblasts exhibit an altered response to TGF-β. J Invest Dermatol 99:650-655, 1992
5. Brown LF, Van-de-Water L, Dvorak HF: Fibrinogen influx and accumulation of crosslinked fibrin in healing wounds and in tumor stroma. Am J Pathol 130:455-465, 1988
6. Clark RAF: Wound repair (review). Curr Opin Cell Biol 1:1000-1008, 1989
7. Collen D, De Cock F, Verstraete M: Immunological distinction between antiplasmin and α-antitrypsin. Thromb Res 7:245-249, 1975
8. Dano K, Andreasen PA, Hansen JH, Kristensen P, Nielsen LS, Skriver L: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44:139-266, 1985
9. Deutsch OB, Mertz ET: Purification from human plasma by affinity chromatography. Science 170:1095-1097, 1970
10. Dvorak HF: Tumors: wounds that do not heal? N Engl J Med 315:1650-1659, 1986
11. Dvorak HF, Senger DR, Dvorak AM: Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev 1:41-73, 1983
12. Feinberg AP, Vogelstein B: A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 137:266-271, 1984
13. Freshney RI: Culture of Animal Cells: A Manual of Basic Technique. Alan R. Liss, Inc.: New York, 1983.
14. Granelli-Piperno A, Reich E: A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 148:223-232, 1978
15. Grinnell F: Fibronectin and wound healing. J Cell Biochem 26:107-116, 1984
16. Haisa M, Okochi H, Grotendorst GR: Elevated levels of PDGF alpha receptors in keloid fibroblasts contribute to an enhanced response to PDGF. J Invest Dermatol 103:560-563, 1994
17. Keski-Oja J, Raghow R, Sawdey M, Loskutoff DJ, Postlethwaite AE, Kang AE, Moses HL: Regulation of RNAs for type-1 plasminogen activator inhibitor, fibronectin, and type I procollagen by transforming growth factor β. J Biol Chem 263:3111-3115, 1988
18. Knighton DR, Hunt TK, Thakral KK, Goodson WH III: Role of platelets and fibrin in healing sequence: an in vivo study of angiogenesis and collagen synthesis. Ann Surg 196:379-388, 1982
19. Kruithof EKO: Plasminogen activator inhibitor type I: biochemical, biological and clinical aspects. Fibrinolysis 2:59-68, 1988
20. Laiho M, Saksela O, Keski-Oja K: Transforming growth factor β alters plasminogen activator activities in human skin fibroblasts. Exp Cell Res 164:399-407, 1986
21. Laiho M, Saksela O, Keski-Oja J: Transforming growth factor-β induction of type-1 plasminogen activator inhibitor. J Biol Chem 262:17467-17474, 1987
22. Laug WE, Cao XR, T'Ang A, Pasquale S, Mundy R, Coensgen-Lina M, Weissman B: Complex expression of the gene coding for plasminogen activators and their inhibitors in Hela-smooth muscle cell hybrids. Cell Growth Differ 3:191-198, 1992
23. Laug WE, Cao XR, Yu YB, Shimada H, Kruithof EKO: Inhibition of invasion of H T 1080 sarcoma cells expressing recombinant plasminogen activator inhibitor. Cancer Res 53:6051-6057, 1993
24. Lyons RM, Keski-Oja J, Moses HL: Proteolytic activation of latent transforming growth factor-β from fibroblast conditioned medium. J Cell Biol 106:1659-1665, 1988
25. Mignatti P, Robbins E, Rifkin DB: Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell 47:487-498, 1986
26. Mirshahi M, Azzarone B, Soria J, Mirshahi F, Soria C: The role of fibroblasts in organization and degradation of a fibrin clot. J Lab Clin Med 117:274-281, 1991
27. Montgomery AMP, De Clerck YA, Langley KL, Reisfeld RA, Mueller BM: Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways. Cancer Res 53:693-700, 1993
28. Mueller BM, Yu YB, Laug WE: Overexpression of plasminogen activator inhibitor-2 in human melanoma cells inhibits spontaneous metastasis in SCID mice. Proc Natl Acad Sci USA 92:205-209, 1995
29. Myles ME, Russell JD, Trupin JS, Smith JC, Russell SB: Keloid fibroblasts are refractory to inhibition of DNA synthesis by phorbol esters. J Biol Chem 267:9014-9020, 1992
30. Plow EF, Freney DE, Plescia J, Miles LA: The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol 103:2411-2420, 1986
31. 1. In: Sporns MB, Roberts AB (eds.). Peptide Growth Factors and Their Receptors. Vol. 1. Springer-Verlag, Berlin, 419-472, 1990
32. Ross R: The fibroblasts and wound repair. Biol Rev 43:51-69, 1968
33. Russell SB, Trupin JS, Kennedy RZ, Russell JD, Davidson JM: Glucocorticoid regulation of elastin synthesis in human dermal fibroblasts: down-regulation in fibroblasts from normal dermis but not from keloids. J Invest Dermatol 104:241-245, 1995
34. Russell SB, Trupin JS, Myers JC, Broquist AH, Smith JC, Myles ME, Russell J: Differential glucocorticoid regulation of collagen mRNAs in human dermal fibroblasts. J Biol Chem 264:13730-13735, 1989
35. Russell SB, Trupin KM, Rodriguez-Eaton S, Russell JD, Trupin JS: Reduced growth factor requirement of keloid-derived fibroblasts may account for tumor growth. Proc Natl Acad Sci USA 85:587-591, 1988
36. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning. A Laboratory Manual. 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989
37. Stopelli MP, Tacchetti C, Cubellis MV, Corti A, Hearing VJ, Cassani G, Appella E, Blasi F: Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell 45:657-684, 1986
38. Straight DL, McKee DB: Effect of protease binding by α2-macroglobulin on intrinsic fluorescence. Biochemistry 21:4550-4556, 1982
39. Tuan TL, DiCesare P, Cheung D, Nimni ME: Keloids and hypertrophic scars. In: Nimni ME, Kang AH (eds.). Collagen: Pathobiochemistry. CRC Press, Boca Raton, Florida, 1991
40. Tuan TL, Grinnell F: Fibronectin and fibrinolysis are not required for fibrin gel contraction by human skin fibroblasts. J Cell Physiol 140:577-583, 1989
41. Tuan TL, Song AK, Chang S, Younai S, Nimni ME: In vitro fibroplasia: Matrix contraction, cell growth and collagen production of fibroblasts cultured in 3-dimensional fibrin matrix. Exp Cell Res 223:127-134, 1996
42. Uitto J, Perejda AJ, Abergel RP, Chu ML, Ramirez F: Altered steady state ratio of type I/III procollagen mRNAs correlates with selectively increases type I procollagen synthesis in cultured keloid fibroblasts. Proc Natl Acad Sci USA 82:5935-5943, 1985
43. 1 in renal glomerular cells. Exp Nephrol 1:343-350, 1993
44. Younai S, Nichter L, Wellisz T, Reinisch J, Nimni M, Tuan TL: Modulation of collagen synthesis by transforming growth factor-β in keloid and hypertrophic scar fibroblasts. Ann Plast Surg 33:148-154, 1994